Efficacy and safety of 2 dose regimens of subcutaneous administration of fremanezumab (TEV-48125) versus placebo for the preventive treatment of chronic migraine

Category Primary study
JournalHeadache
Year 2017
This article has no abstract
Epistemonikos ID: 074886dad2d0247697d1577aaf98fff7b6612ded
First added on: Feb 09, 2025